Table 5.
Our Study | Moradi, et al. 29 | Lee, et al. 33 | Shen, et al. 15 | Pratas, et al. 37 | Oliver, et al. 22 | Ghanimi Zamli, et al. 38 | |
---|---|---|---|---|---|---|---|
Research period | 2009–2017 | 1984–2014 | 2008–2014 | 2009–2014 | 2012–2015 | 2014–2015 | 2013–2017 |
Research location | Shanghai, China | United States of America | Los Angeles | Zhejiang, China | France | North Carolina | Malaysia |
Number of ocular syphilis | 213 | 35 | 16 | 13 | 21 | 63 | 10 |
Blindness patients, % (n) | 23% (50) | 21% (7) | 44% (7) | 8% (1) | NR | 6% (4) | 50% (5) |
Mean age, years | 55 | 49 | 43 | 50 | 49 | 45 | 70 |
Male sex, % (n) | 66% (140) | 74% (26) | 100% (16) | 54% (7) | 100% (21) | 94% (59) | 30% (3) |
Known MSM, % (n)* | 10% (14) | 35% (9) | 44% (7) | 0% (0) | 76% (16) | 71% (42) | 0% (0) |
Co‐infection with HIV, % (n) | 3% (7) | 54% (19) | 63% (10) | 8% (1) | 29% (6) | 56% (35) | 0% (0) |
Risk factors for ocular syphilis | Increasing age and higher RPR titres | NR | NR | NR | NR | Male, aged ≥40 years, white, infected with HIV, and higher RPR titre | NR |
CSF‐VDRL reactive† | 84%‡ | 47% | 20% | 25% | 21% | 63% | NR |
Most common type of ocular diagnosis | Optic atrophy, optic neuritis‡ | Pan uveitis | Pan uveitis, posterior uveitis | Chorioretinitis | Posterior uveitis | Uveitis | Posterior uveitis |
Improved vision after treatment | 36%‡ | 33% | 38% | 62% | 75% | 85% | 85% |
NR, result not reported
Percentage calculated of males.
Percentage calculated of those with CSF analysis performed.
Data from 50 cases of blindness.